EPS misses by wide margin. Eton Pharmaceuticals reported GAAP diluted EPS of $0.05 for Q4 2025, falling short of the $0.20 consensus estimate by 75.0%. The company posted adjusted diluted EPS of $0.19, matching the prior quarter’s $0.19 but up sharply from a loss of $0.03 per share a year ago. The gap between GAAP and adjusted results reflects $3.9 million in adjustments, primarily non-cash items that boosted adjusted net income to $5.4 million versus GAAP net income of $1.5 million.
Revenue accelerates past expectations. Q4 revenue of $21.3 million topped the $20.6 million consensus by 3.4%, marking an 82.9% surge from $11.6 million in the year-ago quarter. Revenue held flat sequentially at $21.3 million, suggesting the company has stabilized at a higher run rate following mid-2025 growth. Gross profit reached $13.1 million on cost of revenue of $8.2 million, yielding a 61.5% gross margin. Adjusted EBITDA of $6.2 million reflects improving operating leverage as the specialty pharmaceutical portfolio scales.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.